Drug Profile

RQ 01

Alternative Names: RQ-001; RQ-01

Latest Information Update: 12 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Red Queen Therapeutics
Class Antivirals; Peptides
Mechanism of Action Viral fusion protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I COVID 2019 infections
Research Common cold; Metapneumovirus infections; Middle East respiratory syndrome coronavirus

Most Recent Events

03 Dec 2024 Dana-Farber Cancer Institute and Red Queen expands license agreement for stapled lipopeptide COVID-19 therapeutics
22 Nov 2024 Dana-Farber Cancer Institute and Red Queen enters license agreement for stapled lipopeptide COVID-19 therapeutics
06 Aug 2024 Efficacy and adverse event data from the phase I trial in COVID-2019 infections released by Red Queen Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com